Cancer Gene Therapy Market By Therapy Type (Gene Transfer Therapy, Oncolytic Virotherapy, Gene Editing Therapy); By Vector Type (Viral Vectors, Non-Viral Vectors); By Cancer Indication (Hematological Malignancies, Breast Cancer, Lung Cancer, Prostate Cancer, Pancreatic Cancer, Others); By End User (Hospitals & Cancer Treatment Centers, Academic & Research Institutions, Specialty Clinics, Others); By Region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2024–2030

Cancer Gene Therapy Market: Approved Living-Drug Market Shaped by Solid Tumor Delivery, Vector Engineering, and Next-Generation Immune Reprogramming (Last Updated on: June-2026)

The Global Cancer Gene Therapy Market is projected to grow at a CAGR of 25.8%, rising from USD 2.9 billion in 2024 to USD 10.5 billion by 2030.

 

The Cancer Gene Therapy Market has progressed beyond experimental oncology to become a clinically established, multi-platform treatment field. Its approved therapeutic base includes genetically modified CAR-T cells for hematologic malignancies, tumor-infiltrating lymphocyte therapy for metastatic melanoma, engineered T-cell receptor therapy for synovial sarcoma, oncolytic viral therapy for melanoma lesions, and intravesical adenoviral gene transfer for high-risk bladder cancer. This breadth of approved modalities represents a key differentiating feature of the market.

 

Unlike conventional oncology drugs, cancer gene therapies are built around genetic modification, viral delivery, immune-cell engineering, or local gene expression. Their clinical value is defined by their ability to address specific therapeutic needs, including durable remission in relapsed hematologic malignancies, immune activation in solid tumors, local disease control in organ-confined settings, and patient-specific or off-the-shelf immune reprogramming. This is why the market should not be evaluated as one uniform gene-delivery category. It is a treatment architecture covering ex vivo cell engineering, in vivo gene transfer, oncolytic virotherapy, and emerging gene editing approaches.

 

The market has established a commercial base of approved products while remaining highly responsive to continued technological and clinical innovation. CAR-T therapies continue to anchor the commercial base in hematologic malignancies, while Amtagvi, Tecelra, Imlygic, and Adstiladrin show that cancer gene therapy is expanding into melanoma, synovial sarcoma, bladder cancer, and other solid tumor-directed platforms. The next phase of growth will depend on whether developers can improve solid tumor activity, make viral and non-viral delivery safer, reduce manufacturing delays, and expand treatment access beyond highly specialized cancer centers.

 

Approved Drugs and Therapy Positioning

Cancer gene therapy is most effectively evaluated through the approved products that provide clinical and commercial validation for each therapeutic platform.

In CAR-T cell therapy, Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, Carvykti, and Aucatzyl form the core approved base. These therapies use genetically modified autologous T cells to recognize cancer antigens and kill malignant cells. CD19-directed CAR-T products are used across B-cell acute lymphoblastic leukemia and several lymphoma subtypes, while BCMA-directed CAR-T products are used in relapsed or refractory multiple myeloma. This remains the most commercially and clinically established segment of cancer gene therapy because it has approved products, defined treatment centers, and growing real-world experience.

In multiple myeloma, BCMA-directed CAR-T therapies are moving earlier in the treatment sequence. Carvykti is approved for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy in eligible patients, while Abecma is approved after at least two prior lines of therapy. This is clinically important because earlier use may allow patients to receive therapy before disease burden, marrow reserve, or heavy prior treatment exposure makes cell collection and recovery more difficult.

In tumor-infiltrating lymphocyte therapy, Amtagvi represents a major solid tumor milestone. It is approved for adults with unresectable or metastatic melanoma previously treated with PD-1 therapy and, where appropriate, BRAF-targeted therapy. Amtagvi showed a 31.5% objective response rate in the FDA approval dataset among patients treated within the recommended dose range. Its importance lies in validating tumor-derived immune-cell therapy as a commercial treatment for solid tumors. [FDA – Amtagvi (Lifileucel) Approval]

In engineered T-cell receptor therapy, Tecelra represents one of the most significant recent regulatory approvals. It is a MAGE-A4–directed autologous genetically modified T-cell therapy indicated for adults with unresectable or metastatic synovial sarcoma whose tumors express MAGE-A4 and who are HLA-A*02 positive. The pivotal dataset demonstrated a 43.2% objective response rate. Tecelra is clinically important as it validates an alternative gene therapy approach based on recognition of intracellular tumor antigens presented via HLA molecules, in contrast to CAR-T therapies that primarily target cell-surface antigens. [FDA – Tecelra (Afamitresgene Autoleucel) Approval]

In oncolytic virotherapy, Imlygic remains the approved benchmark. It is a genetically modified herpes simplex virus therapy used for local treatment of unresectable melanoma lesions in the skin and lymph nodes. Its commercial footprint is more limited than CAR-T, but it remains strategically important because it proves that engineered viruses can act as cancer therapies through direct tumor lysis and immune stimulation.

In intravesical gene therapy, Adstiladrin created a distinct local gene transfer model. It uses a non-replicating adenoviral vector to deliver the interferon alfa-2b gene into the bladder for adults with high-risk BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. In the FDA approval summary, the complete response rate was 51%, median duration of response was 9.7 months, and 46% of responding patients remained in complete response for at least one year. This makes Adstiladrin highly relevant because it shows how cancer gene therapy can be delivered locally to an organ cavity instead of through systemic infusion or ex vivo cell engineering. [FDA – Adstiladrin (Nadofaragene Firadenovec) Approval]

Together, these products show that cancer gene therapy is no longer a single-platform field. CAR-T therapies represent ex vivo gene-modified immune-cell therapy in leukemia, lymphoma, and multiple myeloma. Amtagvi represents tumor-derived immune-cell therapy in melanoma. Tecelra represents engineered TCR gene therapy in synovial sarcoma. Imlygic represents oncolytic virotherapy in injectable melanoma lesions. Adstiladrin represents local adenoviral gene transfer in high-risk bladder cancer. This approved-product map gives the market a stronger clinical identity than generic gene therapy positioning.

 

Cancer Gene Therapy Market Segment Analysis

By therapy type, gene transfer therapy represents the most established segment. It includes both ex vivo gene-modified immune-cell therapies and in vivo or localized gene delivery approaches. CAR-T therapies, Tecelra, and Adstiladrin fall within this broader therapeutic framework, as each relies on the delivery or expression of genetic material to generate an antitumor effect. The segment is supported by approved products, clearly defined indications, and established regulatory pathways. Its primary limitation remains delivery complexity, encompassing challenges related to cell manufacturing, viral vector production, and organ-specific administration.

Oncolytic virotherapy occupies a smaller but clinically distinctive segment. Imlygic remains the approved reference product, while newer oncolytic virus programs are being designed to do more than lyse tumor cells. Many platforms now carry immune-stimulating payloads, cytokines, checkpoint-modulating genes, or tumor microenvironment reprogramming tools. The segment is most relevant for accessible lesions, injectable tumors, melanoma, glioblastoma, pancreatic cancer, and other solid tumors where local immune activation may support systemic antitumor response. The challenge is moving from local control to consistent systemic benefit.

Gene editing therapy remains the most pipeline-driven segment. In cancer, editing is often used to improve immune-cell function rather than correct a single inherited defect. CRISPR, TALEN, base-editing, and multiplex-editing approaches are being used to knock out inhibitory receptors, reduce alloreactivity, enhance persistence, create universal donor cells, or make immune cells more resistant to tumor suppression. This segment has strong long-term potential, but clinical adoption will depend on off-target safety, editing precision, chromosomal stability, long-term follow-up, and manufacturing reproducibility.

By vector type, viral vectors remain the backbone of approved cancer gene therapy. Lentiviral and retroviral vectors are central to many ex vivo CAR-T manufacturing processes, adenoviral vectors support intravesical gene transfer, and herpesvirus platforms support oncolytic virotherapy. Viral vectors offer efficient gene delivery and strong regulatory familiarity, but they also create challenges around manufacturing scale, batch release, immunogenicity, payload capacity, and cost.

Non-viral vectors are gaining strategic relevance but remain less clinically mature in oncology. Lipid nanoparticles, plasmid DNA, transposon systems, electroporation, and polymer-based systems are being studied for cancer vaccines, in vivo immune-cell engineering, and local gene delivery. Their appeal lies in repeat-dosing potential, manufacturing flexibility, and lower viral-vector dependence. Their limitation is the need for stronger evidence of durable, tumor-selective delivery in humans.

 

What Is Moving Cancer Gene Therapy Adoption

Cancer gene therapy adoption is being shaped by clinical fit, not broad oncology demand. In hematologic malignancies, approved CAR-T products have already shown that gene-modified immune cells can produce meaningful responses in patients whose disease has relapsed after several treatment lines. The clinical question is now shifting toward earlier use, better sequencing, relapse prevention, and management after antigen escape.

In solid tumors, adoption is increasingly determined by the clinical and operational specificity of each therapeutic platform. Amtagvi, Tecelra, Imlygic, and Adstiladrin each address a different solid tumor problem. Amtagvi uses tumor-derived immune cells in melanoma. Tecelra uses engineered TCR recognition in synovial sarcoma. Imlygic uses local viral oncolysis in melanoma lesions. Adstiladrin uses intravesical adenoviral gene delivery in high-risk bladder cancer. These examples show that successful solid tumor gene therapy is not one pathway; it depends on matching delivery method to tumor biology and treatment setting.

Treatment-center capability represents an additional determinant of adoption. CAR-T requires leukapheresis, manufacturing coordination, lymphodepletion, infusion monitoring, cytokine release syndrome protocols, and neurotoxicity management. TIL therapy requires tumor harvesting and successful cell expansion. TCR therapy requires HLA typing and antigen-expression confirmation. Adstiladrin requires urologic oncology workflows and intravesical administration. These infrastructure requirements make adoption strongest in large cancer centers and integrated specialty networks.

Diagnostic infrastructure is becoming integral to patient selection and treatment delivery. TCR therapy depends on HLA eligibility and antigen expression. CAR-T depends on antigen presence and relapse monitoring. Gene-edited and allogeneic therapies require safety surveillance. Therapeutic cancer vaccines increasingly depend on tumor sequencing, neoantigen selection, and immune profiling. The market will increasingly reward therapies with a clear diagnostic pathway and a defined treatment-eligible patient group.

Manufacturing complexity continues to constrain treatment accessibility and clinical adoption. Autologous gene-modified therapies require patient-specific manufacturing, which creates treatment delays and capacity limits. This is why closed-system manufacturing, automated cell processing, improved vector supply, cryopreserved products, regional manufacturing hubs, and allogeneic approaches are becoming clinically important. Faster and more reliable manufacturing can directly affect whether patients with aggressive cancer remain eligible long enough to receive treatment.

 

Pipeline and Innovation Landscape: Solid Tumor Conversion, Editing Safety, Allogeneic Cells, and Therapeutic Cancer Vaccines

Pipeline activity remains substantial, although the market is supported by an established base of approved therapies. Current development efforts are primarily directed toward addressing the clinical, safety, and delivery limitations of existing products.

The most important pipeline direction is solid tumor conversion. CAR-T therapy has been most successful in blood cancers, where tumor cells are easier to access and target antigens are more clearly validated. Solid tumors require more advanced engineering because they often have heterogeneous antigen expression, poor immune-cell trafficking, dense stroma, hypoxia, suppressive myeloid cells, and checkpoint-mediated exhaustion. Programs targeting Claudin18.2, GD2, HER2, mesothelin, GPC3, MUC1, EGFR, DLL3, CEA, and other tumor-associated antigens are trying to solve these barriers.

Allogeneic cell therapy represents a strategically important area of pipeline development. Off-the-shelf CAR-T, CAR-NK, gamma-delta T-cell, macrophage, and engineered immune-cell programs are designed to reduce patient-specific manufacturing and shorten treatment timelines. Their promise is faster access and standardized production. Their challenge is persistence, immune rejection, graft-versus-host risk, gene-editing safety, and whether they can match autologous products in depth and durability of response.

Therapeutic cancer vaccines are gaining more attention as sequencing and mRNA technologies improve. These vaccines are not preventive vaccines. They are designed to train the immune system against tumor antigens, neoantigens, or cancer-associated proteins after diagnosis. Their most logical clinical settings include minimal residual disease, adjuvant therapy, recurrence prevention, and combination with immune checkpoint inhibitors. Personalized neoantigen vaccines could become especially important where tumor sequencing can identify patient-specific targets.

Immuno-gene therapy is emerging as a distinct area of therapeutic innovation. AAV-based immuno-gene therapies for high-grade gliomas, programmable immune cells for solid tumors, cytokine-armed oncolytic viruses, and CRISPR-enhanced cell therapies all reflect the same direction: using genetic tools to alter immune behavior rather than only replace or insert a single therapeutic gene.

Oncology remains a leading focus of gene therapy development. In ASGCT’s Q2 2025 landscape report, 64% of the 80 gene therapy trials initiated during the quarter were for oncology indications. This supports the view that cancer remains one of the deepest clinical development areas for gene therapy, especially as programs expand across solid tumors, immune-cell engineering, and vector-based platforms.

 

North America Cancer Gene Therapy Market

North America remains the most clinically advanced regional market for cancer gene therapy, supported by the broad U.S. FDA-approved product base, extensive academic oncology infrastructure, certified cell therapy centers, molecular diagnostic capabilities, and established infusion and toxicity-management protocols.

The region’s competitive advantage is primarily driven by treatment-system readiness rather than patient volume alone. Approved CAR-T therapies require cell therapy units, leukapheresis coordination, lymphodepleting chemotherapy, trained immune-effector-cell teams, and long-term follow-up. Amtagvi requires tumor tissue procurement and specialized cell expansion. Tecelra requires HLA typing and MAGE-A4 confirmation. Adstiladrin requires urologic oncology coordination and intravesical administration. These workflows favor large academic medical centers, comprehensive cancer centers, and specialty oncology networks.

The most commercially relevant U.S. patient populations are concentrated in indications with approved therapies. Non-Hodgkin lymphoma is expected to account for 79,320 new U.S. cases in 2026, and myeloma is expected to account for 36,000 new U.S. cases. These diseases directly support the current CAR-T base. Melanoma, bladder cancer, and synovial sarcoma are also important because they connect to Amtagvi, Adstiladrin, and Tecelra. Not all diagnosed patients are eligible for gene therapy, but these indication-specific pools explain where clinical demand is most relevant. [NCI NHL Cancer Stat Facts]

Real-world registry activity provides an important indicator of cellular therapy adoption in the United States. CIBMTR reported information on 10,347 first CAR-T recipients as of September 2023, showing that CAR-T has moved beyond isolated academic use into a structured national cellular therapy data ecosystem. This is important for the Cancer Gene Therapy Market because long-term safety, relapse patterns, secondary malignancy monitoring, manufacturing outcomes, and survival follow-up are now being captured at scale. [ScienceDirect Study on Cellular]

Treatment-center readiness has also emerged as a practical measure of market adoption. After the 2024 Breyanzi label expansion, more than 100 U.S. treatment centers were certified to administer the therapy. While this reflects one commercial CAR-T product rather than the whole market, it shows how approved gene-modified cell therapies are moving through certified treatment networks instead of standard community infusion pathways. This supports the view that North America’s advantage lies not only in FDA approvals, but in treatment infrastructure, registry follow-up, cell therapy accreditation, and payer documentation systems. [Association of Cancer Care Centers]

Reimbursement and clinical documentation remain central to adoption across North America. Payers typically require confirmed diagnosis, prior therapy history, biomarker eligibility, treatment-center certification, performance status, and evidence of clinical need. For gene-modified cellular therapy, documentation delays can affect manufacturing timelines and patient eligibility. As a result, clinical operations, payer authorization, and patient navigation are part of the market’s real adoption infrastructure.

 

Recent Developmental Direction in the Cancer Gene Therapy Market

In February 2024, FDA approved Amtagvi for unresectable or metastatic melanoma after prior PD-1 therapy and, where appropriate, BRAF-targeted therapy. This made tumor-infiltrating lymphocyte therapy a regulated commercial treatment option and gave solid tumor cell therapy a stronger approval pathway.

In April 2024, FDA expanded the role of BCMA-directed CAR-T therapies in relapsed or refractory multiple myeloma. Carvykti moved into use after at least one prior line of therapy in eligible patients, while Abecma moved into use after at least two prior lines. This showed that gene-modified cell therapy is moving earlier in blood cancer treatment, where patient fitness and disease burden can affect treatment feasibility.

In August 2024, FDA approved Tecelra for MAGE-A4-positive, HLA-A*02-restricted unresectable or metastatic synovial sarcoma after prior chemotherapy. This was a major milestone because it validated engineered T-cell receptor gene therapy and introduced a diagnostic-dependent treatment model into solid tumor oncology.

In November 2024, FDA approved Aucatzyl for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This added another CD19-directed genetically modified autologous T-cell therapy to the approved base and reinforced adult ALL as an important gene-modified cell therapy indication. [FDA CGT Products]

In June 2025, FDA removed REMS requirements for currently approved CAR-T cell immunotherapies while keeping risk communication through labeling, boxed warnings, and medication guides. This regulatory shift is important because it may reduce administrative burden for treatment centers while keeping cytokine release syndrome and neurotoxicity warnings central to clinical monitoring.

In 2026, China’s approval of satri-cel for gastric cancer created a major global signal for solid tumor CAR-T therapy. While outside the FDA pathway, it is important for the broader market because solid tumors have been the hardest area for CAR-T development. It suggests that region-specific approvals may begin reshaping global expectations for engineered cell therapy in gastric and other epithelial cancers.

 

Competitive Landscape and Market Positioning

The Cancer Gene Therapy Market is dominated by organizations with established oncology development capabilities, cell and viral vector manufacturing infrastructure, regulatory expertise, and access to specialized treatment networks. Competitive dynamics are not defined by a single technology platform but are distributed across CAR-T therapy, tumor-infiltrating lymphocyte therapy, T-cell receptor gene therapy, oncolytic virotherapy, intravesical gene transfer, gene editing approaches, allogeneic cell therapies, and therapeutic cancer vaccines.

Companies with approved CAR-T products maintain the strongest commercial positioning due to established treatment-center networks, scalable manufacturing systems, physician familiarity, and defined reimbursement pathways. Their next competitive focus is on expanding into earlier lines of therapy, improving safety profiles, accelerating manufacturing timelines, and strengthening relapse-management strategies.

TIL and TCR developers are primarily focused on solid tumors, where clinical response validation is more complex but differentiation potential is higher. Competitive advantage in these segments depends on tumor selection, cellular potency, companion diagnostic integration, and durability of response. Oncolytic virus developers compete through optimized payload design, tumor selectivity, localized delivery strategies, and combination approaches. Gene editing and allogeneic platforms are differentiated by scalability, persistence, safety, and their ability to achieve autologous-like outcomes in an off-the-shelf format.

Overall, the market is shifting from platform-level innovation toward execution-driven differentiation. Success increasingly depends on demonstrating targeted tumor engagement, effective immune activation, measurable clinical benefit, and safe integration into established oncology care pathways.

 

Evolving Market Landscape

The Cancer Gene Therapy Market is expected to remain highly competitive as it operates at the convergence of immunotherapy, precision medicine, vector engineering, cell manufacturing, and molecular diagnostics. Its current clinical foundation is already established through CAR-T therapies and approved gene therapy products such as Amtagvi, Tecelra, Imlygic, and Adstiladrin.

Hematologic malignancies will remain the most established commercial base because they have validated antigens, measurable disease, and experienced treatment centers. Solid tumors will decide the market’s next phase. Melanoma, synovial sarcoma, bladder cancer, and gastric cancer have already produced important signals, but broader success in lung, breast, ovarian, pancreatic, glioblastoma, and gastrointestinal cancers will require better targeting, improved delivery, and more durable immune activation.

Viral vector–based gene transfer approaches are expected to continue anchoring the near-term market. Gene editing, allogeneic cells, therapeutic cancer vaccines, and non-viral vectors will shape the longer-term direction. The most successful products will not be those with the broadest gene therapy label, but those that solve a defined clinical problem with a clear patient selection pathway, manageable toxicity, reliable manufacturing, and measurable treatment durability.

 

Cancer Gene Therapy Market Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 2.9 Billion
Revenue Forecast in 2030	USD 10.5 Billion
Overall Growth Rate	CAGR of 25.8% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024–2030)
Segmentation	By Therapy Type, Vector Type, Cancer Indication, End User, Geography
By Therapy Type	Gene Transfer Therapy, Oncolytic Virotherapy, Gene Editing Therapy
By Vector Type	Viral Vectors, Non-Viral Vectors
By Cancer Indication	Hematological Malignancies, Breast Cancer, Lung Cancer, Others
By End User	Hospitals and Cancer Centers, Academic Institutions, Specialty Clinics
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Germany, U.K., China, Japan, Brazil, India, South Korea
Market Drivers	1) Rising cancer incidence globally 2) Regulatory support for accelerated approvals 3) Technological innovation in gene editing and vector delivery
Customization Option	Available upon request